Dialysis-related transcriptomic profiling: The pivotal role of heparanase

Experimental Biology and Medicine

Volumn 239, Issue 1, 2014, Pages 52-64

  Zaza, Gianluigi ^a   Masola, Valentina ^a   Granata, Simona ^a   Pontrelli, Paola ^b   Sallustio, Fabio ^b   Gesualdo, Loreto ^b   Gambaro, Giovanni ^c   Grandaliano, Giuseppe ^d   Lupo, Antonio ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

Author keywords

hemodialysis; heparanase; microarray; microinflammation; Peritoneal dialysis; proteoglycans

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENTARY DNA; HEPARANASE; MESSENGER RNA; PROTEOGLYCAN; BETA GLUCURONIDASE;

ADULT; ANTHROPOMETRY; ARTICLE; CELL ISOLATION; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE EXPRESSION; HEMODIALYSIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEAL DIALYSIS; PRINCIPAL COMPONENT ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TRANSCRIPTOMICS; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; UPREGULATION;

ADULT; BIOLOGICAL MARKERS; FEMALE; GLUCURONIDASE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PROTEOGLYCANS; RENAL INSUFFICIENCY, CHRONIC; UP-REGULATION;

EID: 84891958419     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370213506678     Document Type: Article

References (75)

1. Bloembergen WE,Port FK,Mauger EA,Wolfe RA.A comparison of cause of death between patients treated with hemodialysis and peritoneal dialysis.J Am Soc Nephrol. 1995;6:184-91.
2. Haddy FJ,Meyer TW.Uremia.N Engl J Med. 2007;357:1316-25.
3. Coresh J,Astor BC,Greene T,Eknoyan G,Levey AS.Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey.Am J Kidney Dis. 2003;41:1-12.
4. Hamer RA,El Nahas AM.The burden of chronic kidney disease.BMJ. 2006;332:563-4.
5. Grassmann A,Gioberge S,Moeller S,Brown G.ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends.Nephrol Dial Transplant. 2005;20:2587-93.
6. Foley RN,Parfrey PS.Cardiovascular disease and mortality in ESRD.J Nephrol. 1998;11:239-45.
7. Cibulka R,Racek J.Metabolic disorders in patients with chronic kidney failure.Physiol Res. 2007;56:697-705.
8. Ritz E.Metabolic syndrome and kidney disease.Blood Purif. 2008;26:59-62.
9. Charra B.Fluid balance, dry weight, and blood pressure in dialysis.Hemodial Int. 2007;11:21-31.
10. Depner TA.Uremic toxicity: urea and beyond.Semin Dial. 2001;14:246-51.
11. Granata S,Zaza G,Simone S,Villani G,Latorre D,Pontrelli P,Carella M,Schena FP,Grandaliano G,Pertosa G.Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease.BMC Genomics. 2009;10:388-388.
12. Gesualdo L,Pertosa G,Grandaliano G,Schena FP.Cytokines and bioincompatibility.Nephrol Dial Transplant. 1998;13:1622-6.
13. Zaza G,Pontrelli P,Pertosa G,Granata S,Rossini M,Porreca S,Staal FJ,Gesualdo L,Grandaliano G,Schena FP.Dialysis-related systemic microinflammation is associated with specific genomic patterns.Nephrol Dial Transplant. 2008;23:1673-81.
14. Pesce F,Pathan S,Schena FP.From -omics to personalized medicine in nephrology: integration is the key.Nephrol Dial Transplant. 2013;28:24-8.
15. Zaza G,Granata S,Sallustio F,Grandaliano G,Schena FP.Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.Clin Exp Immunol. 2010;159:268-80.
16. Vivekanandan-Giri A,Slocum JL,Buller CL,Basrur V,Ju W,Pop-Busui R,Lubman DM,Kretzler M,Pennathur S.Urine glycoprotein profile reveals novel markers for chronic kidney disease.Int J Proteomics. 2011;2011:214715-214715.
17. Salmon AH,Ferguson JK,Burford JL,Gevorgyan H,Nakano D,Harper SJ,Bates DO,Peti-Peterdi J.Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction.J Am Soc Nephrol. 2012;23:1339-50.
18. Couchman JR,Pataki CA.An introduction to proteoglycans and their localization.J Histochem Cytochem. 2012;60:885-97.
19. Taylor KR,Gallo RL.Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation.FASEB J. 2006;20:9-22.
20. Cohen-Mazor M,Sela S,Mazor R,Ilan N,Vlodavsky I,Rops AL,van der Vlag J,Cohen HI,Kristal B.Are primed polymorphonuclear leukocytes contributors to the high heparanase levels in hemodialysis patients?.Am J Physiol Heart Circ Physiol. 2008;294:H651-8.
21. Xu X,Quiros RM,Maxhimer JB,Jiang P,Marcinek R,Ain KB,Platt JL,Shen J,Gattuso P,Prinz RA.Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas: a potential role in tumor metastasis.Clin Cancer Res. 2003;9:5968-79.
22. The Gene Ontology project in 2008.Nucleic Acid Res. 2008;36:D440-4.
23. Golub TR,Slonim DK,Tamayo P,Huard C,Gaasenbeek M,Mesirov JP,Coller H,Loh ML,Downing JR,Caligiuri MA,Bloomfield CD,Lander ES.Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.Science. 1999;286:531-7.
24. Storey JD,Tibshirani R.Statistical significance for genomewide studies.Proc Natl Acad Sci USA. 2003;100:9440-5.
25. Frey H,Schroeder N,Manon-Jensen T,Iozzo RV,Schaefer L.Biological interplay between proteoglycans and their innate immune receptors in inflammation.FEBS J. 2013;280:2165-79.
26. Strand ME,Herum KM,Rana ZA,Skrbic B,Askevold ET,Dahl CP,Vistnes M,Hasic A,Kvaløy H,Sjaastad I,Carlson CR,Tønnessen T,Gullestad L,Christensen G,Lunde IG.Innate immune signaling induces expression and shedding of the heparan sulfate proteoglycan syndecan-4 in cardiac fibroblasts and myocytes, affecting inflammation in the pressure-overloaded heart.FEBS J. 2013;280:2228-47.
27. Collins AJ,Foley RN,Gilbertson DT,Chen SC.The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis.Clin J Am Soc Nephrol. 2009;4:S5-11.
28. Kendrick J,Teitelbaum I.Strategies for improving long-term survival in peritoneal dialysis patients.Clin J Am Soc Nephrol. 2010;5:1123-31.
29. Kaysen GA.The microinflammatory state in uremia. Causes and potential consequences.J Am Soc Nephrol. 2001;12:1549-57.
30. Osterud B,Bjorklid E.Role of monocytes in atherogenesis.Physiol Rev. 2003;83:1069-112.
31. Hansson GK.Inflammation, atherosclerosis and coronary artery disease.N Engl J Med. 2005;352:1685-95.
32. Yeun JY,Levine RA,Mantadilok V,Kaysen GA.C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients.Am J Kidney Dis. 2000;35:469-76.
33. Zimmermann J,Herrlinger S,Pruy A,Metzger T,Wanner C.Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.Kidney Int. 1999;55:648-58.
34. Akahoshi T,Kobayashi N,Hosaka S,Sekiyama N,Wada C,Kondo H.In vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure.Nephrol Dial Transplant. 1995;10:2244-9.
35. Herbelin A,Ureña P,Nguyen AT,Zingraff J,Descamps-Latscha B.Elevated circulating levels of interleukin-6 in patients with chronic renal failure.Kidney Int. 1991;39:954-60.
36. Lonnemann G,van der Meer JW,Cannon JG,Dinarello CA,Koch KM,Granolleras C,Deschodt G,Shaldon S.Induction of tumor necrosis factor during extracorporeal blood purification.N Engl J Med. 1987;317:963-4.
37. Nakanishi I,Moutabarrik A,Okada N,Kitamura E,Hayashi A,Syouji T,Namiki M,Ishibashi M,Zaid D,Tsubakihara Y.Interleukin-8 in chronic renal failure and dialysis patients.Nephrol Dial Transplant. 1994;9:1435-42.
38. Kim S,Oh J,Kim S,Chung W,Ahn C,Kim SG,Oh KH.Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.Nephrol Dial Transplant. 2009;24:2899-908.
39. Hoff CM.In vitro biocompatibility performance of Physioneal.Kidney Int Suppl. 2003;88:S57-74.
40. Pajek J,Kveder R,Bren A,Gucek A,Bucar M,Skoberne A,Waniewski J,Lindholm B.Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study.Nephrol Dial Transplant. 2009;24:1617-25.
41. Glik A,Douvdevani A.T lymphocytes: the "cellular" arm of acquired immunity in the peritoneum.Perit Dial Int. 2006;26:438-48.
42. Walter R,Mischak H,Haller H.Haemodialysis, atherosclerosis and inflammation-identifying molecular mechanisms of chronic vascular disease in ESRD patients.Nephrol Dial Transplant. 2002;17:24-9.
43. Bartold PM,Harkin DG,Bignold LP.Proteoglycans synthesized by human polymorphonuclear leucocytes in vitro.Immunol Cell Biol. 1989;67:9-17.
44. Wilflingseder J,Perco P,Kainz A,Korbély R,Mayer B,Oberbauer R.Biocompatibility of haemodialysis membranes determined by gene expression of human leucocytes: a crossover study.Eur J Clin Invest. 2008;38:918-24.
45. Friedrich B,Alexander D,Janessa A,Häring HU,Lang F,Risler T.Acute effects of hemodialysis on cytokine transcription profiles: evidence for C-reactive protein-dependency of mediator induction.Kidney Int. 2006;70:2124-2130.
46. Zaza G,Granata S,Rascio F,Pontrelli P,Dell'Oglio MP,Cox SN,Pertosa G,Grandaliano G,Lupo A.A specific immune transcriptomic profile discriminates chronic kidney disease patients in predialysis from hemodialyzed patients.BMC Med Genomics. 2013;6:17.-17.
47. Schaefer L,Schaefer RM.Proteoglycans: from structural compounds to signaling molecules.Cell Tissue Res. 2010;339:237-46.
48. Wu YJ,La Pierre DP,Wu J,Yee AJ,Yang BB.The interaction of versican with its binding partners.Cell Res. 2005;15:483-94.
49. Wight TN.Versican: a versatile extracellular matrix proteoglycan in cell biology.Curr Opin Cell Biol. 2002;14:617-23.
50. Norian JM,Malik M,Parker CY,Joseph D,Leppert PC,Segars JH,Catherino WH.Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas.Reprod Sci. 2009;16:1153-64.
51. Lemire JM,Chan CK,Bressler S,Miller J,LeBaron RG,Wight TN.Interleukin-1beta selectively decreases the synthesis of versican by arterial smooth muscle cells.J Cell Biochem. 2007;101:753-66.
52. Tammela T,Enholm B,Alitalo K,Paavonen K.The biology of vascular endothelial growth factors.Cardiovasc Res. 2005;65:550-63.
53. Chung AS,Ferrara N.Developmental and pathological angiogenesis.Ann Rev Cell Dev Biol. 2011;27:563-84.
54. Osada-Oka M,Ikeda T,Imaoka S,Akiba S,Sato T.VEGF-enhanced proliferation under hypoxia by an autocrine mechanism in human vascular smooth muscle cells.J Atheroscler Thromb. 2008;15:26-33.
55. Dvorak HF,Brown LF,Detmar M,Dvorak AM.Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.Am J Pathol. 1995;146:1029-39.
56. Keck PJ,Hauser SD,Krivi G,Sanzo K,Warren T,Feder J,Connolly DT.Vascular permeability factor, an endothelial cell mitogen related to PDGF.Science. 1989;246:1309-12.
57. Scholze A,Bladbjerg EM,Sidelmann JJ,Diederichsen AC,Mickley H,Nybo M,Argraves WS,Marckmann P,Rasmussen LM.Plasma concentrations of extracellular matrix protein fibulin-1 are related to cardiovascular risk markers in chronic kidney disease and diabetes.Cardiovasc Diabetol. 2013;12:6-6.
58. Masola V,Onisto M,Zaza G,Lupo A,Gambaro G.A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition.J Transl Med. 2012;10:213-213.
59. Masola V,Gambaro G,Tibaldi E,Brunati AM,Gastaldello A,D'Angelo A,Onisto M,Lupo A.Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells.J Biol Chem. 2012;287:1478-88.
60. Masola V,Maran C,Tassone E,Zin A,Rosolen A,Onisto M.Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion.BMC Cancer. 2009;28:304-304.
61. Dempsey LA,Brunn GJ,Platt JL.Heparanase, a potential regulator of cell-matrix interactions.Trends Biochem Sci. 2000;25:349-51.
62. Barash U,Cohen-Kaplan V,Dowek I,Sanderson RD,Ilan N,Vlodavsky I.Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.FEBS J. 2010;277:3890-903.
63. Ilan N,Elkin M,Vlodavsky I.Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.Int J Biochem Cell Biol. 2006;38:2018-39.
64. Rao G,Ding HG,Huang W,Le D,Maxhimer JB,Oosterhof A,van Kuppevelt T,Lum H,Lewis EJ,Reddy V,Prinz RA,Xu X.Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis.Diabetologia. 2011;54:1527-38.
65. Baker AB,Gibson WJ,Kolachalama VB,Golomb M,Indolfi L,Spruell C,Zcharia E,Vlodavsky I,Edelman ER.Heparanase regulates thrombosis in vascular injury and stent-induced flow disturbance.J Am Coll Cardiol. 2012;59:1551-60.
66. Rops AL,van den Hoven MJ,Veldman BA,Salemink S,Vervoort G,Elving LD,Aten J,Wetzels JF,van der Vlag J,Berden JH.Urinary heparanase activity in patients with Type 1 and Type 2 diabetes.Nephrol Dial Transplant. 2012;27:2853-61.
67. Ben Arush MW,Shafat I,Ben Barak A,Shalom RB,Vlodavsky I,Ilan N.Plasma heparanase as a significant marker of treatment response in children with Hodgkin lymphoma: pilot study.Pediatr Hematol Oncol. 2009;26:157-64.
68. Ngkelo A,Meja K,Yeadon M,Adcock I,Kirkham PA.LPS induced inflammatory responses in human peripheral blood mononuclear cells is mediated through NOX4 and Giα dependent PI-3kinase signalling.J Inflamm (Lond). 2012;9:1-1.
69. Amore A,Coppo R.Immunological basis of inflammation in dialysis.Nephrol Dial Transplant. 2002;17:16-24.
70. Pertosa G,Grandaliano G,Gesualdo L,Schena FP.Clinical relevance of cytokine production in hemodialysis.Kidney Int Suppl. 2000;76:S104-11.
71. Schindler R,Eichert F,Lepenies J,Frei U.Blood components influence cytokine induction by bacterial substances.Blood Purif. 2001;19:380-7.
72. Baccheschi S,Sereni L,De Nitti C,Barbucci R,Tetta C.Blood tubing and cytokine production: effect of sterilization.Ren Fail. 2001;23:411-8.
73. Szeto CC,Kwan BC,Chow KM,Lai KB,Chung KY,Leung CB,Li PK.Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients.Clin J Am Soc Nephrol. 2008;3:431-6.
74. Guth HJ,Gruska S,Kraatz G.The measurement of cytokine production capacity during dialysis-a new dynamic method for the evaluation of biocompatibility?.Int J Artif Organ. 2000;23:675-9.
75. Fischer WH,Jagels MA,Hugli TE.Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg).J Immunol. 1999;162:453-9.